ERBB2 and neoplasm: Results show that patients positive for HER2+ tumor niche indeed exhibit worse survival outcomes than those in the negative group, in both the inner-validation set (p = 0.0002) and external-validation set (p = 0.097), with only the former being statistically significant (Figures 15A and 15D).